Nanobodies News and Research

RSS

UCI researchers develop new technology to rapidly hypermutate antibodies

Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies.

8 Dec 2020

Researchers use novel technology to prevent destruction of specific proteins inside cells

Columbia researchers have created a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells.

8 Dec 2020

Novel modular design approach to antibody nanocage generation

A new study shows the benefits of using computational design to create antibody nanocages that have the required orientation.

7 Dec 2020

Bioelectronic rapid test for COVID-19

A recent study presents a bioelectronic sensor platform to detect protein at the single-molecule level that is simple, rapid, and robust enough for widespread POC (point-of-care) or bedside application.

18 Nov 2020

Nanobodies: unharnessed potential in COVID-19 treatment

A new study published in the Journal of Biomolecular Structure and Dynamics in October 2020 discusses the use of nanobodies in diagnosing and treating this deadly disease.

16 Nov 2020

Bispecific sybodies show potential against SARS-CoV-2

As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.

12 Nov 2020

Llama antibodies could be a potent nanoweapon against COVID-19

Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.

5 Nov 2020

Nanobodies efficiently neutralize SARS-CoV-2 in cells

Two separate studies have identified nanobodies - which could be produced less expensively than monoclonal antibodies - that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells.

5 Nov 2020

Researchers identify antibodies that prevent SARS-CoV-2 from infecting human cells

The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.

5 Nov 2020

Synthetic antibody may prevent coronavirus from infecting human cells

By screening hundreds of synthetic antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells.

4 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

NeutrobodyPlex nanobodies help monitor SARS-CoV-2 immune responses

Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.

23 Sep 2020

Molecular dynamic simulations reveal detailed spike-ACE2 interactions

The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.

23 Sep 2020

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.

4 Sep 2020

Canadian Coalition for COVID-19 releases 51 promising nanobodies

A group of Canadian companies has published 51 antibodies that show promising ability to bind the COVID-19 virus which could result in neutralizing the virus.

From SignalChem Biotech Inc. 20 Aug 2020

Synthetic nanobodies prevent SARS-CoV-2 infection

A team of researchers from the University of California San Francisco has created a powerful nasal spray or inhaler that can provide high-grade protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The report is presently available on the bioRvix* preprint server.

13 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Llama nanobodies block SARS-CoV-2 infection in vitro

Now, a team of scientists at the United Kingdom's Rosalind Franklin Institute may have a surprising solution for the coronavirus pandemic, which has killed more than 574,000 people worldwide.

14 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

Integration of diverse set of species and environments can enhance biomedical research cycle

In an article published today in Science, a multidisciplinary research team from more than 10 universities and research institutes outlines how integrating a more diverse set of species and environments could enhance the biomedical research cycle.

3 Jul 2020